Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children
The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2002-03, Vol.29 (5), p.383-389 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 389 |
|---|---|
| container_issue | 5 |
| container_start_page | 383 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 29 |
| creator | SCHNEIDER, D. T CHO, J LAWS, H. J DILLOO, D GÖBEL, U NÜRNBERGER, W |
| description | The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 +/- 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMT-related complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores > or =10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P < 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores > or =10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 +/- 0.15 vs 0.27 +/- 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following BMT. As it indicates fatal events early, it may be helpful for parent information and even more for the early establishment of intensified supportive treatment. The O-PRISM score may therefore be a valuable parameter for the evaluation of different strategies for BMT and supportive treatment. |
| doi_str_mv | 10.1038/sj.bmt.1703384 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_71555231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199909795</galeid><sourcerecordid>A199909795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-811e9ae89a0fe61680f505d1aadf8c7b10afa635a47e190a49a17956ce0022cc3</originalsourceid><addsrcrecordid>eNp1kV2LEzEUhoMobq3eeilBUfRiajL5mMnlsvixsLLi6nU4Tc-0qemkJhmX_RH-Z1NaWBC8CAmc5-S8nIeQ55wtOBP9-7xdLHdlwTsmRC8fkBmXnW6U0OohmbFW940Q2pyRJzlvGeNSMvWYnHFuuOnabkb-3GDyECj-hjBB8XGkcaBlgzSOLoa49q5W97jyUJJ3NPn880DsYioQfLmjb6-br98ub768o9nFhHSIIcRbP64p1McaR6xtyzgi3UFK8ZaWBGPeBxjLcZ4fqdv4sEo4PiWPBggZn53uOfnx8cP3i8_N1fWny4vzq8Yp3pWm5xwNYG-ADai57tmgmFpxgNXQu27JGQyghQLZITcMpAHeGaUdMta2zok5eXP8d5_irwlzsTufHYYaCuOUbceVUq3gFXz1D7iNUxprNttq2bZS6Hrm5OV_Ka61FILJ-5lrCGg3CKFscgzTYQfZnnNjDDM1ZQUXR9ClmHPCwe6Tr7u7s5zZg3Sbt7ZKtyfpteHFafy03OHqHj9ZrsDrEwC56hyqAOfzPSeU6iQX4i92GrXp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216643304</pqid></control><display><type>article</type><title>Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SCHNEIDER, D. T ; CHO, J ; LAWS, H. J ; DILLOO, D ; GÖBEL, U ; NÜRNBERGER, W</creator><creatorcontrib>SCHNEIDER, D. T ; CHO, J ; LAWS, H. J ; DILLOO, D ; GÖBEL, U ; NÜRNBERGER, W</creatorcontrib><description>The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 +/- 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMT-related complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores > or =10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P < 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores > or =10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 +/- 0.15 vs 0.27 +/- 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following BMT. As it indicates fatal events early, it may be helpful for parent information and even more for the early establishment of intensified supportive treatment. The O-PRISM score may therefore be a valuable parameter for the evaluation of different strategies for BMT and supportive treatment.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1703384</identifier><identifier>PMID: 11919727</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adolescent ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Bone Marrow Transplantation - mortality ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Child ; Child, Preschool ; Children ; Complications ; Evaluation ; Fatalities ; Female ; Graft-versus-host reaction ; Health services ; Hematologic Neoplasms - diagnosis ; Hematologic Neoplasms - mortality ; Hematologic Neoplasms - therapy ; Hemorrhage ; Humans ; Infant ; Male ; Mathematical analysis ; Medical sciences ; Parameters ; Patients ; Pediatrics ; Prognosis ; Retrospective Studies ; Risk Assessment ; Severity of Illness Index ; Stem cell transplantation ; Survival Analysis ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Bone marrow transplantation (Basingstoke), 2002-03, Vol.29 (5), p.383-389</ispartof><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2002 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Mar 2002</rights><rights>Macmillan Publishers Limited 2002.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-811e9ae89a0fe61680f505d1aadf8c7b10afa635a47e190a49a17956ce0022cc3</citedby><cites>FETCH-LOGICAL-c517t-811e9ae89a0fe61680f505d1aadf8c7b10afa635a47e190a49a17956ce0022cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13557413$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11919727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHNEIDER, D. T</creatorcontrib><creatorcontrib>CHO, J</creatorcontrib><creatorcontrib>LAWS, H. J</creatorcontrib><creatorcontrib>DILLOO, D</creatorcontrib><creatorcontrib>GÖBEL, U</creatorcontrib><creatorcontrib>NÜRNBERGER, W</creatorcontrib><title>Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 +/- 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMT-related complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores > or =10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P < 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores > or =10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 +/- 0.15 vs 0.27 +/- 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following BMT. As it indicates fatal events early, it may be helpful for parent information and even more for the early establishment of intensified supportive treatment. The O-PRISM score may therefore be a valuable parameter for the evaluation of different strategies for BMT and supportive treatment.</description><subject>Adolescent</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone Marrow Transplantation - mortality</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Complications</subject><subject>Evaluation</subject><subject>Fatalities</subject><subject>Female</subject><subject>Graft-versus-host reaction</subject><subject>Health services</subject><subject>Hematologic Neoplasms - diagnosis</subject><subject>Hematologic Neoplasms - mortality</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Mathematical analysis</subject><subject>Medical sciences</subject><subject>Parameters</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Severity of Illness Index</subject><subject>Stem cell transplantation</subject><subject>Survival Analysis</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV2LEzEUhoMobq3eeilBUfRiajL5mMnlsvixsLLi6nU4Tc-0qemkJhmX_RH-Z1NaWBC8CAmc5-S8nIeQ55wtOBP9-7xdLHdlwTsmRC8fkBmXnW6U0OohmbFW940Q2pyRJzlvGeNSMvWYnHFuuOnabkb-3GDyECj-hjBB8XGkcaBlgzSOLoa49q5W97jyUJJ3NPn880DsYioQfLmjb6-br98ub768o9nFhHSIIcRbP64p1McaR6xtyzgi3UFK8ZaWBGPeBxjLcZ4fqdv4sEo4PiWPBggZn53uOfnx8cP3i8_N1fWny4vzq8Yp3pWm5xwNYG-ADai57tmgmFpxgNXQu27JGQyghQLZITcMpAHeGaUdMta2zok5eXP8d5_irwlzsTufHYYaCuOUbceVUq3gFXz1D7iNUxprNttq2bZS6Hrm5OV_Ka61FILJ-5lrCGg3CKFscgzTYQfZnnNjDDM1ZQUXR9ClmHPCwe6Tr7u7s5zZg3Sbt7ZKtyfpteHFafy03OHqHj9ZrsDrEwC56hyqAOfzPSeU6iQX4i92GrXp</recordid><startdate>20020301</startdate><enddate>20020301</enddate><creator>SCHNEIDER, D. T</creator><creator>CHO, J</creator><creator>LAWS, H. J</creator><creator>DILLOO, D</creator><creator>GÖBEL, U</creator><creator>NÜRNBERGER, W</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20020301</creationdate><title>Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children</title><author>SCHNEIDER, D. T ; CHO, J ; LAWS, H. J ; DILLOO, D ; GÖBEL, U ; NÜRNBERGER, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-811e9ae89a0fe61680f505d1aadf8c7b10afa635a47e190a49a17956ce0022cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone Marrow Transplantation - mortality</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Complications</topic><topic>Evaluation</topic><topic>Fatalities</topic><topic>Female</topic><topic>Graft-versus-host reaction</topic><topic>Health services</topic><topic>Hematologic Neoplasms - diagnosis</topic><topic>Hematologic Neoplasms - mortality</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Mathematical analysis</topic><topic>Medical sciences</topic><topic>Parameters</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Severity of Illness Index</topic><topic>Stem cell transplantation</topic><topic>Survival Analysis</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCHNEIDER, D. T</creatorcontrib><creatorcontrib>CHO, J</creatorcontrib><creatorcontrib>LAWS, H. J</creatorcontrib><creatorcontrib>DILLOO, D</creatorcontrib><creatorcontrib>GÖBEL, U</creatorcontrib><creatorcontrib>NÜRNBERGER, W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHNEIDER, D. T</au><au>CHO, J</au><au>LAWS, H. J</au><au>DILLOO, D</au><au>GÖBEL, U</au><au>NÜRNBERGER, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2002-03-01</date><risdate>2002</risdate><volume>29</volume><issue>5</issue><spage>383</spage><epage>389</epage><pages>383-389</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>The O-PRISM score was introduced for risk assessment in children transferred to intensive care following BMT. The aim of this study is to determine the prognostic value of a serial evaluation of the O-PRISM score. Ninety-three children, 58 allogeneic-related and 35 unrelated BMT, were evaluated. At weekly intervals, the O-PRISM was calculated based on the standard PRISM score and the three additional variables CRP, GVHD and hemorrhage. Overall survival was 0.51 +/- 0.05 (48/93 patients). Seventeen children died of recurrent disease and 28 of BMT-related complications. High O-PRISM scores significantly correlated with adverse outcome. The relative risks of DOC of patients with scores > or =10 compared to patients with lower scores were: day 0: 3.9 (95% confidence-interval: 1.1-13.7, P = 0.02), day 7: 2.0 (0.7-6.2, P = 0.20), day 14: 5.2 (1.9-14.0, P = 0.001), day 21: 5.6 (1.9-16.5, P = 0.001), day 28: 11.5 (3.8-100.9, P < 0.001), day 35: 7.3 (1.9-27.7, P = 0.001). As early as day 0, children with scores > or =10 points showed a higher cumulative incidence of DOC than patients with lower scores (0.69 +/- 0.15 vs 0.27 +/- 0.05, P = 0.02). The O-PRISM score represents a useful clinical parameter for serial risk assessment following BMT. As it indicates fatal events early, it may be helpful for parent information and even more for the early establishment of intensified supportive treatment. The O-PRISM score may therefore be a valuable parameter for the evaluation of different strategies for BMT and supportive treatment.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>11919727</pmid><doi>10.1038/sj.bmt.1703384</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2002-03, Vol.29 (5), p.383-389 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71555231 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow Bone marrow transplantation Bone Marrow Transplantation - mortality Bone marrow, stem cells transplantation. Graft versus host reaction Child Child, Preschool Children Complications Evaluation Fatalities Female Graft-versus-host reaction Health services Hematologic Neoplasms - diagnosis Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hemorrhage Humans Infant Male Mathematical analysis Medical sciences Parameters Patients Pediatrics Prognosis Retrospective Studies Risk Assessment Severity of Illness Index Stem cell transplantation Survival Analysis Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Homologous Treatment Outcome |
| title | Serial evaluation of the oncological pediatric risk of mortality (O-PRISM) score following allogeneic bone marrow transplantation in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A17%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serial%20evaluation%20of%20the%20oncological%20pediatric%20risk%20of%20mortality%20(O-PRISM)%20score%20following%20allogeneic%20bone%20marrow%20transplantation%20in%20children&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=SCHNEIDER,%20D.%20T&rft.date=2002-03-01&rft.volume=29&rft.issue=5&rft.spage=383&rft.epage=389&rft.pages=383-389&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1703384&rft_dat=%3Cgale_proqu%3EA199909795%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216643304&rft_id=info:pmid/11919727&rft_galeid=A199909795&rfr_iscdi=true |